循环肿瘤DNA在肾细胞癌中的应用研究进展

doi:10.3969/j.issn.1673-8640.2020.09.023

摘要/Abstract

摘要：

肾细胞癌（RCC）是全球第七大最常见癌症。由于早期症状不明显,很多患者被诊断时已经处于疾病晚期,通常预后不良。循环肿瘤DNA（ctDNA）是存在于血液或体液中由肿瘤衍生的片段DNA,能够反映整个肿瘤基因组的信息,而且容易获得,在肿瘤诊断、预后评估、疾病复发监测、治疗效果监测以及化疗耐药监测等方面具有重要的临床应用价值。近年来的研究结果表明,ctDNA在RCC中同样具有临床应有价值。文章对ctDNA在RCC临床诊治中的应用研究进展作一综述。

关键词: 循环肿瘤DNA, 基因突变, 甲基化, 肾细胞癌, 临床研究

Abstract:

Renal cell carcinoma（RCC） is the 7th most common cancer in the world. Due to the lack of symptoms in early stage,many patients are diagnosed with advanced disease and with poor prognosis. Circulating tumor DNA（ctDNA） is tumor-derived fragment DNA in blood or body fluid,which can reflect entire tumor genome and is easy to obtain. It is potential in tumor diagnosis,prognosis assessment,disease recurrence monitoring,therapeutic effect monitoring and chemotherapy resistance monitoring. Recent studies have shown that ctDNA is also clinically valuable in RCC. This review describes the recent progress in the application of ctDNA in the clinical diagnosis and treatment of RCC.

Key words: Circulating tumor DNA, Gene mutation, Methylation, Renal cell carcinoma, Clinical research

中图分类号:

R446.7

师越, 董冬. 循环肿瘤DNA在肾细胞癌中的应用研究进展[J]. 检验医学, 2020, 35(9): 952-956.

SHI Yue, DONG Dong. Research progress of circulating tumor DNA in renal cell carcinoma[J]. Laboratory Medicine, 2020, 35(9): 952-956.

参考文献 35

[1]	SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J]. CA Cancer J Clin,2018,68(1):7-30.
[2]	ESCUDIER B,PORTA C,SCHMIDINGER M,et al.Renal cell carcinoma:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2016,27(suppl 5):v58-v68.
[3]	MOTZER R J,TANNIR N M,MCDERMOTT DF,et al.Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma[J]. N Engl J Med,2018,378(14):1277-1290.
[4]	POWLES T,LACKNER M R,OUDARD S,et al.Randomized open-label phase Ⅱ trial of apitolisib(GDC-0980),a novel inhibitor of the PI3K/mammalian target of rapamycin pathway,versus everolimus in patients with metastatic renal cell carcinoma[J]. J Clin Oncol,2016,34(14):1660-1668.
[5]	SHIN S J,KIM T,SUNG H H,et al.Novel predictive models of early death less than 1 year in patients with metastatic renal cell carcinoma after treatment with first-line tyrosine kinase inhibitors[J]. Clin Genitourin Cancer,2019,17(6):e1137-e1146.
[6]	LI G,PAVLICK D,CHUNG J H,et al.Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy[J]. J Gastrointest Oncol,2019,10(5):831-840.
[7]	STRICKLER J H,BANKS K C,NAGY R J,et al.Blood-based genomic profiling of circulating cell-free tumor DNA(ctDNA) in 1 397 patients(pts) with colorectal cancer(CRC)[J]. J Clin Oncol,2017,35(Suppl 4):584.
[8]	MAIA M C,BERGEROT P G,DIZMAN N,et al.Association of circulating tumor DNA(ctDNA) detection in metastatic renal cell carcinoma(mRCC) with tumor burden[J]. Kidney Cancer,2017,1(1):65-70.
[9]	WAN J,ZHU L,JIANG Z,et al.Monitoring of plasma cell-free DNA in predicting postoperative recurrence of clear cell renal cell carcinoma[J]. Urol Int,2013,91(3):273-278.
[10]	FENG G,YE X,FANG F,et al.Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma[J]. Dis Markers,2013,34(2):105-111.
[11]	YAMAMOTO Y,UEMURA M,NAKANO K,et al.Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma[J]. Oncotarget,2018,9(29):20467-20475.
[12]	YAMAMOTO Y,UEMURA M,FUJITA M,et al.Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma[J]. Cancer Sci,2019,110(2):617-628.
[13]	KHAGI Y,GOODMAN A M,DANIELS G A,et al.Hypermutated circulating tumor DNA:correlation with response to checkpoint inhibitor-based immunotherapy[J]. Clin Cancer Res,2017,23(19):5729-5736.
[14]	LE D T,DURHAM J N,SMITH K N,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science,2017,357(6349):409-413.
[15]	LE D T,DURHAM J N,SMITH K N,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science,2017,357(6349):409-413.
[16]	CHOUEIRI T K,HESSEL C,HALABI S,et al.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk(Alliance A031203 CABOSUN randomised trial):progression-free survival by independent review and overall survival update[J]. Eur J Cancer,2018,94:115-125.
[17]	GILL D,HAHN A W,SONPAVDE G,et al.Immunotherapy of advanced renal cell carcinoma:current and future therapies[J]. Hum Vaccin Immunother,2016,12(12):2997-3004.
[18]	ZHAO H,NOLLEY R,CHAN A M W,et al. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation[J]. Cancer Biol Ther,2017,18(11):863-871.
[19]	BEUSELINCK B,JEAN-BAPTISTE J,SCHÖFFSKI P,et al. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib[J]. BJU Int,2016,118(6):890-901.
[20]	PAL S K,SONPAVDE G,AGARWAL N,et al.Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma[J]. Eur Urol,2017,72(4):557-564.
[21]	BRODZIAK A,SOBCZUK P,BARTNIK E,et al.Drug resistance in papillary RCC:from putative mechanisms to clinical practicalities[J]. Nat Rev Urol,2019,16(11):655-673.
[22]	ZHOU J,LUO J,WU K,et al.Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies[J]. Oncogene,2016,35(35):4663-4674.
[23]	SCHRÖCK A,LEISSE A,DE VOS L,et al. Free-circulating methylated DNA in blood for diagnosis,staging,prognosis,and monitoring of head and neck squamous cell carcinoma patients:an observational prospective cohort study[J]. Clin Chem,2017,63(7):1288-1296.
[24]	THAM C,CHEW M,SOONG R,et al.Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer[J]. Cancer,2014,120(20):3131-3141.
[25]	FENNER A.Kidney cancer:Methylation panel predicts RCC outcome[J]. Nat Rev Urol,2017,14(1):8-9.
[26]	WEI J H,HADDAD A,WU K J,et al.A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma[J]. Nat Commun,2015,6:8699.
[27]	SKRYPKINA I,TSYBA L,ONYSHCHENKO K,et al.Concentration and methylation of cell-free DNA from blood plasma as diagnostic markers of renal cancer[J]. Dis Markers,2016,2016:3693096.
[28]	JUNG M,ELLINGER J,GEVENSLEBEN H,et al.Cell-free SHOX2 DNA methylation in blood as a molecular staging parameter for risk stratification in renal cell carcinoma patients:a prospective observational cohort study[J]. Clin Chem,2019,65(4):559-568.
[29]	LIN Y L,WANG Y P,LI H Z,et al.Aberrant promoter methylation of PCDH17(protocadherin 17) in serum and its clinical significance in renal cell carcinoma[J]. Med Sci Monit,2017,23:3318-3323.
[30]	COSTA V L,HENRIQUE R,DANIELSEN S A,et al.TCF21 and PCDH17 methylation:an innovative panel of biomarkers for a simultaneous detection of urological cancers[J]. Epigenetics,2011,6(9):1120-1130.
[31]	XIN J,XU R,LIN S,et al.Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma[J]. Oncol Lett,2016,12(2):1265-1270.
[32]	SANTONI M,PIVA F,DE GIORGI U,et al.Autophagic gene polymorphisms in liquid biopsies and outcome of patients with metastatic clear cell renal cell carcinoma[J]. Anticancer Res,2018,38(10):5773-5782.
[33]	LU H,BUSCH J,JUNG K,et al.Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients[J]. Clin Chim Acta,2016,452:109-119.
[34]	BALL M W,GORIN M A,GUNER G,et al.Circulating tumor DNA as a marker of therapeutic response in patients with renal cell carcinoma:a pilot study[J]. Clin Genitourin Cancer,2016,14(5):e515-e520.
[35]	CORRÒC,HEJHAL T,POYET C,et al. Detecting circulating tumor DNA in renal cancer:an open challenge[J]. Exp Mol Pathol,2017,102(2):255-261.